With a mission to bring innovative products from around the world to the Canadian market, Exzell Pharma aims to provide new and effective therapeutic options to patients in areas of unmet need.
After being incorporated into Biolab in 2022, the possibilities and motivation for Exzell Pharma have increased even more to become a leading source of safe, effective and affordable healthcare products in Canada.
The acquisition of Exzell Pharma represents a major growth opportunity for both the Brazilian and Canadian markets, through the expansion of the product portfolio. The purchase of Exzell Pharma also offers a significant growth opportunity for the Biolab group, by establishing an international export platform from Canada.
La mission de Biolab, qui est d’améliorer le bien-être, est soutenue par sa présence internationale grandissante et son approche collaborative des soins de santé. Forte d’une équipe de plus de 4000 professionnels et de l’un des plus importants effectifs de vente au Brésil, Biolab entretient des relations solides avec les fournisseurs de soins de santé, réalisant chaque année plus de 320 000 visites. Ce vaste réseau témoigne de son expérience et consolide sa position de partenaire de confiance en soins de santé, permettant la mise en œuvre de solutions qui répondent aux besoins en constante évolution des patients.
As part of the Biolab & Co. , Exzell Pharma benefits from the expertise, resources, and strategic vision of this dynamic organization. This collaboration enables Exzell, a proudly Canadian company, to expand its healthcare offerings across Canada, focusing on both human and animal health. With Biolab’s trust in the Canadian market and its support, Exzell is well-positioned to forge new partnerships and develop innovative products that improve quality of life and promote better health outcomes across borders.